Ascendiant Capital Markets Comments on Pro-Dex FY2026 Earnings

Pro-Dex, Inc. (NASDAQ:PDEX) – Ascendiant Capital Markets issued their FY2026 earnings per share (EPS) estimates for shares of Pro-Dex in a research note issued to investors on Monday, May 11th. Ascendiant Capital Markets analyst E. Woo forecasts that the medical instruments supplier will post earnings per share of $3.16 for the year. Ascendiant Capital Markets currently has a “Buy” rating and a $70.00 target price on the stock.

Separately, Weiss Ratings reaffirmed a “hold (c+)” rating on shares of Pro-Dex in a research report on Friday, May 1st. One analyst has rated the stock with a Buy rating and one has issued a Hold rating to the company’s stock. Based on data from MarketBeat, Pro-Dex currently has an average rating of “Moderate Buy” and an average price target of $70.00.

Pro-Dex Stock Performance

Shares of Pro-Dex stock opened at $60.78 on Wednesday. The stock has a market cap of $193.89 million, a PE ratio of 16.79 and a beta of -0.12. The business has a fifty day simple moving average of $51.67 and a 200-day simple moving average of $43.53. The company has a quick ratio of 2.14, a current ratio of 3.67 and a debt-to-equity ratio of 0.32. Pro-Dex has a 12 month low of $23.47 and a 12 month high of $62.15.

Pro-Dex (NASDAQ:PDEX) last released its quarterly earnings data on Thursday, April 30th. The medical instruments supplier reported $1.20 earnings per share for the quarter, topping the consensus estimate of $0.62 by $0.58. The business had revenue of $19.95 million during the quarter, compared to analyst estimates of $17.90 million. Pro-Dex had a return on equity of 22.78% and a net margin of 16.08%.

Institutional Trading of Pro-Dex

Several hedge funds and other institutional investors have recently modified their holdings of PDEX. Cubist Systematic Strategies LLC acquired a new stake in shares of Pro-Dex in the first quarter worth $170,000. Jane Street Group LLC acquired a new stake in shares of Pro-Dex in the first quarter worth $321,000. Geode Capital Management LLC boosted its position in shares of Pro-Dex by 93.2% in the second quarter. Geode Capital Management LLC now owns 51,668 shares of the medical instruments supplier’s stock worth $2,255,000 after buying an additional 24,927 shares during the period. JPMorgan Chase & Co. raised its holdings in shares of Pro-Dex by 67.7% during the second quarter. JPMorgan Chase & Co. now owns 35,877 shares of the medical instruments supplier’s stock worth $1,566,000 after acquiring an additional 14,479 shares in the last quarter. Finally, New York State Common Retirement Fund purchased a new stake in shares of Pro-Dex during the second quarter worth $105,000. Institutional investors and hedge funds own 15.28% of the company’s stock.

Pro-Dex Company Profile

Pro-Dex, Inc is a designer and manufacturer of precision drive systems and fluid management products serving the dental, medical, industrial and energy markets. The company specializes in high-speed, brushless micromotors and controllers, as well as pneumatic and fluid control devices, providing both standard and custom-engineered solutions for original equipment manufacturers.

Its product portfolio includes high-speed dental handpieces, turbine systems, rotary and reciprocating micro-drives, along with integrated fluid delivery systems.